A detailed history of Susquehanna International Group, LLP transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 15,000 shares of TSVT stock, worth $37,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,000
Previous 41,979 64.27%
Holding current value
$37,500
Previous $161,000 56.52%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$3.6 - $5.79 $32,198 - $51,785
8,944 Added 27.07%
41,979 $161,000
Q1 2024

May 07, 2024

SELL
$3.09 - $6.0 $169,319 - $328,776
-54,796 Reduced 62.39%
33,035 $176,000
Q4 2023

Feb 14, 2024

SELL
$1.57 - $4.58 $85,855 - $250,457
-54,685 Reduced 38.37%
87,831 $375,000
Q3 2023

Nov 14, 2023

BUY
$3.14 - $11.2 $166,978 - $595,593
53,178 Added 59.52%
142,516 $558,000
Q2 2023

Aug 11, 2023

SELL
$8.45 - $12.48 $666,519 - $984,397
-78,878 Reduced 46.89%
89,338 $904,000
Q1 2023

May 16, 2023

BUY
$9.21 - $14.98 $1.36 Million - $2.22 Million
147,935 Added 729.43%
168,216 $1.72 Million
Q4 2022

Feb 14, 2023

SELL
$8.57 - $17.0 $225,622 - $447,559
-26,327 Reduced 56.49%
20,281 $190,000
Q3 2022

Nov 14, 2022

SELL
$12.56 - $17.54 $531,375 - $742,064
-42,307 Reduced 47.58%
46,608 $678,000
Q2 2022

Aug 15, 2022

BUY
$10.55 - $18.81 $153,059 - $272,895
14,508 Added 19.5%
88,915 $1.17 Million
Q1 2022

May 16, 2022

SELL
$11.67 - $26.72 $215,486 - $493,384
-18,465 Reduced 19.88%
74,407 $1.27 Million
Q4 2021

Feb 14, 2022

BUY
$13.77 - $42.56 $1.28 Million - $3.95 Million
92,872 New
92,872 $2.38 Million

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $94.7M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.